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Can hyperhomocysteinemia be linked as a causative agent in the




▪ Many diseases see hyperhomocysteinemia as it progresses, as 
seen in figure 4.
▪ Bakeberg et al, Christine,et al., and Licking, et al, found 
inversely proportional relationships between serum 
homocysteine levels and some aspects of cognition in specific 
populations in PD patients.
▪ Two variables, age and length of disease, amongst several other 
confounding variables, have an association with elevated serum 
homocysteine and cognitive decline in PD, as seen in Figure 5.
▪ Due to confounding variables, it is difficult to isolate 
homocysteine in these studies as the cause of the cognitive 
decline.
▪ If futures studies were able to better support the theory of the 
inverse relationship between homocysteine and cognitive decline 
in PD, treatment and monitoring of the disease could be changed 
and potentially improved.
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Figure 2. PRISMA flow diagram depicting the literature 
review resulting in the three studies evaluated. 
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Year Published 2017 2018 2019
Sample Size 294 680 (456 follow up) 205
Journal Parkinsonism & 
Related Disorders









capacity score (sum of 
UPDRS items 13‐15, 
29&30), and MMSE, 
calculated as 
annualized rates of 
change.
















Serum, collected prior to 





14 𝛍mol/L 15 𝛍mol/L N/A
Outcomes Elevated homocysteine 
was linked with verbal 
memory function and 
semantic fluency 
memory, but an overall 
causal relationship 
between homocysteine 








homocysteine levels are 
associated with a greater 
motor impairment in 
males with Parkinson’s 
disease and poorer 
cognitive performance 
in females with 
Parkinson’s disease.
Critique Study had limited 
exclusion criteria for 
treatment. Treatments, 
like L-dopa, are known 
for altering 
homocysteine levels. 
But they corrected for 
several confounding 
variables.  
Study was sponsored 
by the Michael J. Fox 
Foundation, potentially 
introducing bias. 224 
patients lost to follow 
up. But there is a large 
sample size and only 
included patients 
without treatment. 
Study didn’t include 
patients with advanced 
PD and the ACE-R does 
no assess for executive 
function. But they 
controlled for 
medications, age, and 
gender. 
Table 1: Table comparing the demographics of three articles4,5,6 analyzed in this review.
DISCUSSION
Figure 3. Line graph depicting a comparison in the 
change in Mini Mental Status Exam (MSSE) score 
from baseline to follow-up in those with elevated and 
normal homocysteine serum levels at baseline from 
Christine, et al.
▪ Parkinson's disease (PD) is the second most prevalent 
neurodegenerative condition after Alzheimer’s disease
▪ There are few laboratory tests to track PD’s progress due it’s 
unknown pathophysiology
▪ Homocysteine, though its mechanism is unknown, may be a 
reliable predictor of cognitive decline
▪ Several aspects of homocysteine could lead to cognitive decline 
including (as seen in figure 1):
▪ Interrupts DNA methylation1
▪ Stimulates NMDA to an 
excitotoxic response1
▪ Triggers neuronal apoptosis1
▪ Increases free radicals1
▪ Interrupts mitochondrial
function1
▪ Hyperhomocysteinemia is linked to vitamin B and folate 
deficiencies, as well as taking L-dopa
▪ The goal of this research is to analyze research articles for a 
relationship between homocysteine serum levels and cognitive 
decline in PD
Figure 1. Homocysteine’s effects on neurons2. 
Figure 4. Homocysteine is 
believed to contribute to a battery 
of metabolic, cardiovascular, and 
skeletal disorders6. 
Figure 5. Though the 
pathophysiology of PD is not 
entirely understood, several 
factors are believed to 
contribute, making it difficult to 
isolate which ones can be 
attributed to its progression7. 
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